Aurobindo Pharma gets USFDA nod for $494m Tofacitinib

Stock reaction and the key announcement

Aurobindo Pharma shares rose 1.80% to Rs 1,489.95 after the company said it received final approval from the US Food and Drug Administration (USFDA) for Tofacitinib Tablets. The approval covers 5 mg and 10 mg strengths, and the company said the product is scheduled for immediate launch. The development adds another US approval to Aurobindo’s generic portfolio, a segment where regulatory clearances directly influence near-term product flow. The company’s update also arrived alongside other strategic manufacturing news around biologics, signalling a broader push across multiple drug platforms.

What the USFDA approved

Aurobindo said the tablets are bioequivalent and therapeutically equivalent to the reference listed drug Xeljanz Tablets. The reference product is listed under PF Prism C.V., a Pfizer group entity referenced in the company’s note. The approval allows Aurobindo to manufacture and market the drug in the US, which remains the largest market for many Indian generic drugmakers. Immediate launch plans suggest the company is operationally ready on supply and distribution, subject to typical commercial execution requirements.

Where the product will be made

The company said Tofacitinib tablets will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary. Manufacturing site readiness is a critical element in US launches, since supply continuity and compliance depend on the approved facility. By naming the site, Aurobindo tied the approval to a specific production base and clarified that it has in-house capacity aligned to the launch timeline.

Market size: $194 million (IQVIA MAT April 2026)

Aurobindo cited IQVIA MAT data for the 12 months ended April 2026, estimating the US market size for Tofacitinib tablets at approximately USD 494 million. This figure provides a reference point for the addressable opportunity the company is entering with its generic. While the company did not disclose pricing assumptions or expected sales, the market size estimate helps investors frame the commercial significance of the approval. The MAT period and end date also matter because they indicate the estimate is based on recent demand and prescription trends up to April 2026.

What Tofacitinib is used for

The company detailed the approved indications, focusing on adult patients with immune-mediated inflammatory conditions. Tofacitinib tablets are indicated for moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis. Aurobindo added that the use is relevant where patients have had an inadequate response or intolerance to prior standard therapies such as methotrexate or other disease-modifying antirheumatic drugs. In ulcerative colitis, the company specified use in patients who have not responded adequately or are intolerant to TNF (tumour necrosis factor) blockers.

ANDA count after the latest clearance

After the approval, Aurobindo said it now has a total of 586 ANDA approvals from the USFDA. This includes 561 final approvals and 25 tentative approvals. ANDA counts are tracked closely because they indicate both the breadth of a company’s US pipeline and its execution track record with regulators. Final approvals enable marketing, while tentative approvals typically await expiry of patents or exclusivities before launch.

Biologics facility milestone: TheraNym in Telangana

Separately, the company has operationalized a mammalian cell culture biologics facility called TheraNym in Telangana, described in the update as India’s largest facility of its kind. The facility is positioned to support biologics manufacturing needs, expanding Aurobindo’s capabilities beyond small-molecule generics. The market note also described the site as part of the company’s entry into the Biologics CDMO segment. Alongside the Tofacitinib approval, the TheraNym milestone adds context on how the company is building manufacturing platforms across both conventional generics and biologics.

MSD named as anchor customer for the facility

Aurobindo said MSD, known as Merck & Co. in the US and Canada, will serve as the anchor customer for the biologics facility. The company added that the site has been established to support domestic and export supply requirements, subject to applicable approvals and customer requirements. Naming an anchor customer is relevant because it indicates early demand visibility for the facility, even as the pace and scale of supply depend on approvals and customer specifications.

What this means for investors and the sector

The immediate takeaway for markets was reflected in the stock’s 1.80% rise to Rs 1,489.95 on the announcement. From an operating perspective, the USFDA approval enables a near-term product launch in a defined US market where Aurobindo has provided a USD 494 million reference opportunity. In parallel, the TheraNym facility and the MSD anchor-customer detail highlight a strategic expansion into biologics manufacturing for domestic and export supply, within regulatory guardrails. Aurobindo also reiterated its broader business scope, spanning the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services.

Key facts at a glance

Conclusion

Aurobindo Pharma’s latest USFDA final approval for Tofacitinib tablets adds a new immediately launchable product to its US generics portfolio, with the company citing a USD 494 million US market size. Alongside this, the company’s biologics manufacturing milestone at TheraNym and the identification of MSD as an anchor customer indicate parallel capacity building for domestic and export supply, subject to applicable approvals and customer requirements.